RS52224B - Upotreba inhibitora il-18 kod poremećaja preosetljivosti - Google Patents

Upotreba inhibitora il-18 kod poremećaja preosetljivosti

Info

Publication number
RS52224B
RS52224B YU11904A YUP11904A RS52224B RS 52224 B RS52224 B RS 52224B YU 11904 A YU11904 A YU 11904A YU P11904 A YUP11904 A YU P11904A RS 52224 B RS52224 B RS 52224B
Authority
RS
Serbia
Prior art keywords
inhibitors
hypersensitivity disorders
moiety
protein
fused
Prior art date
Application number
YU11904A
Other languages
English (en)
Inventor
Yolande Chvatchko
Marie Kosco-Vilbois
Original Assignee
Laboratoires Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono Sa filed Critical Laboratoires Serono Sa
Publication of YU11904A publication Critical patent/YU11904A/sh
Publication of RS52224B publication Critical patent/RS52224B/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Upotreba proteina koji vezuje IL-18 (IL-18BP), fuzionisanog proteina, funkcionalnog derivata koji uključuje spojeni deo, gde je taj deo polietilen glikol (PEG), za dobijanje leka za lečenje i/ili prevenciju kontaktne preosetljivosti.Prijava sadrži još 14 patentnih zahteva.
YU11904A 2001-08-10 2002-08-01 Upotreba inhibitora il-18 kod poremećaja preosetljivosti RS52224B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01118811 2001-08-10
EP02100735 2002-06-20

Publications (2)

Publication Number Publication Date
YU11904A YU11904A (sh) 2006-08-17
RS52224B true RS52224B (sr) 2012-10-31

Family

ID=26076673

Family Applications (1)

Application Number Title Priority Date Filing Date
YU11904A RS52224B (sr) 2001-08-10 2002-08-01 Upotreba inhibitora il-18 kod poremećaja preosetljivosti

Country Status (26)

Country Link
US (1) US20040247598A1 (sr)
EP (1) EP1423138B1 (sr)
JP (1) JP4301942B2 (sr)
KR (1) KR20040030948A (sr)
CN (1) CN100500210C (sr)
AR (1) AR035274A1 (sr)
AU (1) AU2002331376B2 (sr)
BR (1) BRPI0211827B8 (sr)
CA (1) CA2456247C (sr)
CY (1) CY1116137T1 (sr)
DK (1) DK1423138T3 (sr)
EA (1) EA006745B1 (sr)
ES (1) ES2533253T3 (sr)
HR (1) HRP20040071B1 (sr)
HU (1) HU230377B1 (sr)
IL (2) IL160230A0 (sr)
ME (1) ME00547B (sr)
MX (1) MXPA04001230A (sr)
NO (1) NO335688B1 (sr)
PL (1) PL227130B1 (sr)
PT (1) PT1423138E (sr)
RS (1) RS52224B (sr)
SI (1) SI1423138T1 (sr)
UA (1) UA78516C2 (sr)
WO (1) WO2003013577A2 (sr)
ZA (1) ZA200400442B (sr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552908A (en) * 2004-06-30 2009-11-27 Atsuo Sekiyama Indicator agent for noninflammatory stress response and use thereof
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
ATE529433T1 (de) 2005-06-10 2011-11-15 Ares Trading Sa Verfahren zur reinigung eines il-18-bindenden proteins
BRPI0711908B8 (pt) 2006-05-25 2021-05-25 Glaxo Group Ltd anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.
WO2012081650A1 (ja) * 2010-12-16 2012-06-21 株式会社明治 遅延型過敏症軽減剤
WO2024261470A1 (en) * 2023-06-20 2024-12-26 Apollo Ap43 Limited Anti-il-18 antibody therapy for treating atopic dermatitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
AU2901899A (en) * 1998-03-09 1999-09-27 Vertex Pharmaceuticals Incorporated 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
WO2000012555A1 (fr) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Proteine de liaison de l'interleukine 18
WO2000071719A1 (en) * 1999-05-20 2000-11-30 Hyseq, Inc. Interleukin-1 hy2 materials and methods
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
EP1423138A2 (en) 2004-06-02
MXPA04001230A (es) 2004-05-27
CA2456247C (en) 2013-09-10
AU2002331376B2 (en) 2007-06-14
CA2456247A1 (en) 2003-02-20
AR035274A1 (es) 2004-05-05
JP4301942B2 (ja) 2009-07-22
HRP20040071A2 (en) 2004-10-31
BRPI0211827B8 (pt) 2021-05-25
BRPI0211827B1 (pt) 2019-07-23
US20040247598A1 (en) 2004-12-09
HU230377B1 (hu) 2016-03-29
WO2003013577A3 (en) 2003-09-25
HUP0401323A3 (en) 2006-01-30
EA200400296A1 (ru) 2004-06-24
PL227130B1 (pl) 2017-10-31
WO2003013577A2 (en) 2003-02-20
IL160230A (en) 2014-11-30
DK1423138T3 (en) 2015-02-23
HUP0401323A2 (hu) 2004-10-28
KR20040030948A (ko) 2004-04-09
EP1423138B1 (en) 2014-12-24
SI1423138T1 (sl) 2015-04-30
JP2005501080A (ja) 2005-01-13
CN1568193A (zh) 2005-01-19
PL368231A1 (en) 2005-03-21
NO20040370L (no) 2004-03-23
EA006745B1 (ru) 2006-04-28
PT1423138E (pt) 2015-02-09
NO335688B1 (no) 2015-01-19
ME00547B (me) 2011-12-20
HRP20040071B1 (hr) 2015-08-28
YU11904A (sh) 2006-08-17
CN100500210C (zh) 2009-06-17
UA78516C2 (en) 2007-04-10
BR0211827A (pt) 2004-08-31
ZA200400442B (en) 2005-03-30
IL160230A0 (en) 2004-07-25
ES2533253T3 (es) 2015-04-08
CY1116137T1 (el) 2017-02-08
HK1069780A1 (zh) 2005-06-03

Similar Documents

Publication Publication Date Title
CY1108007T1 (el) Φαρμακευτικες συνθεσεις βοτουλινικης τοξινης
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
EA200100872A1 (ru) Композиция валдекоксиба
PT1171143E (pt) Extracto peptidico de tremoco e composicao farmaceutica ou cosmetica ou nutraceutica compreendendo o referido extracto
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
SV2003001103A (es) Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester pc10894
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE259782T1 (de) N-cyanomethylamide als protease-inhibitoren
TNSN07020A1 (en) Her2 antibody composition
NZ534919A (en) Bioactive keratin peptides
RS51737B (sr) Korišćenje inhibitora il-18
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
MA26492A1 (fr) Inhibiteurs de proteases nouveaux et compositions pharmaceutiques les contenant .
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
SE0002202D0 (sv) New peptides
FI20002392A0 (fi) Menetelmä ja valmiste asetaldehydin sitomiseksi, mahalaukussa ja paksusuolessa
BR0213379A (pt) Formulação resistente a derramamento de mascaramento de gosto
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
ATE282607T1 (de) Tryptase-inhibitoren
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales